Arcus Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
RCUS$18.67-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(347) | $(247) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 50 | 45 |
| Depreciation and amortization | 7 | 7 |
| Noncash lease expense | 6 | 5 |
| Amortization of discounts on marketable securities | (7) | (10) |
| Other items, net | 3 | 2 |
| Changes in operating assets and liabilities: | ||
| Receivable from collaboration partners ($— and $6 from a related party) | 23 | 9 |
| Other assets | 1 | 5 |
| Accounts payable (($11) and $29 to a related party) | 2 | 24 |
| Deferred revenue (($55) and ($214) to a related party) | (63) | (214) |
| Other liabilities | (20) | 12 |
| Net cash used in operating activities | (345) | (362) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (463) | (679) |
| Proceeds from maturities of marketable securities | 694 | 858 |
| Proceeds from sales of marketable securities | 17 | 70 |
| Purchases of property and equipment | — | (1) |
| Net cash provided by investing activities | 248 | 248 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock ($— and $14 from a related party) | — | 150 |
| Proceeds from debt issuances, net | — | 49 |
| Proceeds from issuance of common stock pursuant to equity award plans | 26 | 3 |
| Net cash provided by financing activities | 26 | 202 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (71) | 88 |
| Cash, cash equivalents and restricted cash at beginning of period | 225 | 153 |
| Cash, cash equivalents and restricted cash at end of period | $154 | $241 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.